{"nctId":"NCT01256177","briefTitle":"Evaluate the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended Release as Monotherapy in the Treatment of Patients With Bipolar Depression","startDateStruct":{"date":"2010-12"},"conditions":["Bipolar Depression"],"count":361,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: Quetiapine Fumarate (SEROQUEL) Extended Release"]},{"label":"2","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Quetiapine Fumarate (SEROQUEL) Extended Release","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Provision of informed consent prior to any study specific procedures\n* Male and female patients, aged 18 to 65 years, inclusive.\n* Meets Diagnostic and Statistical Manual of Mental Disorders - 4th Edition (DSM-IV) criteria for bipolar disorder I or bipolar II, most recent episode depressed (296.5x and 296.89x).\n* Hamilton Rating Scale for Depression (HAM-D) (17-item) total score of ≥ 20 and HAM-D item 1 (depressed mood) score ≥ 2 at enrolment and randomisation.\n* Patients must be able to understand and comply with the requirements of the study,as judged by the Investigator\n\nExclusion Criteria:\n\n* Patients with a current Diagnostic and Statistical Manual of Mental Disorders - 4th Edition (DSM-IV) diagnosis other than bipolar disorder\n* Patients whose Young Mania Rating Scale (YMRS) total score \\>12 at enrolment and randomisation.\n* Patients with \\>8 mood episodes during the past 12 months at enrolment.\n* Patients whose current episode of depression exceeds 12 months or is less than 4 weeks from enrolment.\n* Patients with a history of non-response to an adequate treatment (6 weeks) with more than 2 classes of antidepressants during their current episode.\n* Alcohol or other substance dependence or abuse as defined by Diagnostic and Statistical Manual of Mental Disorders - 4th Edition (DSM-IV) criteria at enrolment that is not in extended full or extended partial remission (12 months or longer), except caffeine and nicotine dependence.\n* Patients who, in the Investigator's judgment, pose a current serious suicidal or homicidal risk, have a Hamilton Rating Scale for Depression (HAM-D) item 3 score ≥ 3, or have made a suicide attempt within the past 6 months.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline (Visit 2) to End of Study (Week 8) in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score","description":"MADRS total score range: 0 to 60, the higher the score, the more severe, Change : Total MADRS score at week 8 minus score at baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.27","spread":"0.81"},{"groupId":"OG001","value":"-18.48","spread":"0.78"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.8","spread":"0.45"},{"groupId":"OG001","value":"28.5","spread":"0.46"}]}]}]},{"type":"SECONDARY","title":"Montgomery-Asberg Depression Rating Scale (MADRS) Total Score Response (Subjects With ≥50% Reduction From Baseline to Week 8 in MADRS Total Score)","description":"Montgomery-Asberg Depression Rating Scale (MADRS) total score range: 0 to 60, the higher the score, the more severe, Response was defined as ≥50% reduction in MADRS total score from baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null},{"groupId":"OG001","value":"93","spread":null}]}]}]},{"type":"SECONDARY","title":"Montgomery-Asberg Depression Rating Scale (MADRS) Total Score Remission (the Proportion of Subjects With a MADRS Total Score ≤ 12 at Week 8 Assessment)","description":"Montgomery-Asberg Depression Rating Scale (MADRS) total score range: 0 to 60, the higher the score, the more severe, Remission was defined as MADRS total score ≤12","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"88","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Each Assessment in MADRS Total Score","description":"MADRS total score range: 0 to 60, the higher the score, the more severe.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.14","spread":"0.50"},{"groupId":"OG001","value":"-5.62","spread":"0.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.70","spread":"0.64"},{"groupId":"OG001","value":"-10.13","spread":"0.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.05","spread":"0.69"},{"groupId":"OG001","value":"-14.18","spread":"0.69"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.96","spread":"0.76"},{"groupId":"OG001","value":"-16.04","spread":"0.74"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.27","spread":"0.81"},{"groupId":"OG001","value":"-18.48","spread":"0.78"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.8","spread":"0.45"},{"groupId":"OG001","value":"28.5","spread":"0.46"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 8 in HAM-D Total Scores","description":"HAM-D total score range: 0 to 53, the higher the score, the more severe. Change : Total HAM-D score at week 8 minus score at baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.92","spread":"0.61"},{"groupId":"OG001","value":"-15.16","spread":"0.59"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.2","spread":"1.96"},{"groupId":"OG001","value":"23.5","spread":"1.87"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 8 Assessment in the Clinical Global Impression Bipolar - Severity (CGI-BP-S)","description":"CGI-BP severity of illness-Overall bipolar range = 1-7, the higher is the total score,the more severe is the disease. CGI-BP severity of illness-Depression range: 1-7, the higher is the total score, the more severe is the disease","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.73","spread":"0.12"},{"groupId":"OG001","value":"-2.24","spread":"0.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.81","spread":"0.13"},{"groupId":"OG001","value":"-2.28","spread":"0.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","spread":".065"},{"groupId":"OG001","value":"4.6","spread":".067"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","spread":".065"},{"groupId":"OG001","value":"4.6","spread":".068"}]}]}]},{"type":"SECONDARY","title":"The Proportion of Patients at Week 8 With a Clinical Global Impression - Bipolar - Change (CGI-BP-C) of \"Much\" or \"Very Much\" Improved","description":"Clinical Global Impression - Bipolar - Change (CGI-BP-C) of \"much\" or \"Very much\" improved is defined as a change in CGI-BP overall bipolar illness score ≤ 2 where 1 = very much improved, 2 = much improved.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65","spread":null},{"groupId":"OG001","value":"91","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 8 in Item 10 of Montgomery-Asberg Depression Rating Scale (MADRS) for Suicidal Ideation","description":"MADRS item 10 (suicidal ideation) score range: 0 to 6, the higher the score, the more severe, Change: MADRS item 10 score at week 8 minus score at baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.76","spread":"0.06"},{"groupId":"OG001","value":"-0.98","spread":"0.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":".094"},{"groupId":"OG001","value":"1.0","spread":".083"}]}]}]},{"type":"SECONDARY","title":"Incidence of Treatment-emergent Mania (AE of Mania or Hypomania, Defined as Young Mania Rating Scale [YMRS] Score ≥16 on 2 Consecutive Assessments or Final Assessment)","description":"The incidence of treatment-emergent mania is defined as ≥16 of YMRS total score on 2 consecutive assessments or at final assessment, YMRS total score range: 0-60, the higher is the total score the more severe is the disease.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":147},"commonTop":["SOMNOLENCE","DIZZINESS","DRY MOUTH","CONSTIPATION","INSOMNIA"]}}}